Your journey to clearer, healthier eyes starts here with Blue Fin Vision.
Particularly long-term or dose-dependent risks
CANADA CA2601784, the compound patent for semaglutide in Canada, was scheduled to expire in March 2026, however, due to Novo Nordisks failure to pay the required maintenance fees, the patent has lapsed and Novo Nordisk's market exclusivity for semaglutide in Canada officially ended on January 4, 2026
But theres an important distinction: Medical peptides used in healthcare Performance peptides used in sports or research Medical peptides have decades of safety data, while experimental peptides require careful evaluation
Any patient currently on tirzepatide 15 mg who wants to trial retatrutide should discontinue tirzepatide first, allow at least two weeks for GI recovery, and begin retatrutide at the 2 mg starting dose with standard titration [2][4]